European Society for Medical Oncology Congress

Healio.com brings you the highlights from the European Society for Medical Oncology Congress. Refer back to this page often to read the latest news from ESMO, see perspectives and interviews with leading researchers and clinicians, and review archives of past meetings.

ESMO honors several oncology leaders

October 31, 2018
European Society for Medical Oncology honored several oncology leaders during its annual congress. Jean-Charles Soria, MD, PhD, received the…
Meeting NewsPerspective

Neoadjuvant ipilimumab-nivolumab combination induces major pathological response in mismatch repair-deficient colon cancer

October 29, 2018
MUNICH — Neoadjuvant treatment with nivolumab and ipilimumab induced major pathologic response in 100% of patients with early-stage, mismatch…
Meeting News

Nivolumab plus low-dose ipilimumab demonstrates ‘robust’ benefit for certain patients with metastatic colorectal cancer

October 29, 2018
MUNICH — The combination of nivolumab and low-dose ipilimumab may become a new first-line treatment option for patients with microsatellite…
Meeting NewsPerspective

Chemoradiation should remain standard for HPV-positive oropharyngeal cancer

October 22, 2018
MUNICH — Patients with HPV-positive, low-risk oropharyngeal cancer should undergo chemoradiotherapy instead of cetuximab plus radiotherapy…
Meeting NewsPerspective

First-line pembrolizumab a new standard for recurrent, metastatic head and neck squamous cell carcinoma

October 22, 2018
MUNICH — Pembrolizumab prolonged survival compared with standard first-line systemic therapy for patients with recurrent or metastatic head and…
Meeting NewsPerspective

Post-hoc analysis supports pembrolizumab’s benefit in recurrent head, neck squamous cell carcinoma

October 22, 2018
MUNICH — A post-hoc analysis of the randomized phase 3 KEYNOTE-040 trial presented at European Society for Medical Oncology Congress showed a…
Meeting News

SD-101 plus pembrolizumab induces response in recurrent, metastatic head and neck cancer

October 22, 2018
MUNICH — The addition of SD-101 to pembrolizumab induced a promising response rate among patients with recurrent or metastatic head and neck…
Meeting News

Vandetanib shows promise for advanced thyroid cancer

October 22, 2018
MUNICH — Vandetanib induced tumor shrinkage that persisted throughout multiple treatment lines for patients with advanced unresectable…
Meeting News

Lenvatinib plus pembrolizumab effective for thyroid cancer subset

October 22, 2018
MUNICH — The combination of lenvatinib and pembrolizumab appeared effective for a small cohort of patients with metastatic anaplastic or poorly…
Meeting NewsPerspective

Olaparib confers ‘unprecedented’ PFS benefit in ovarian cancer

October 21, 2018
MUNICH — Maintenance olaparib significantly improved PFS among women with advanced ovarian cancer who harbored BRCA1 or BRCA2 mutations…